Kaleido Biosciences, Inc. (KLDO)

Kaleido Biosciences, Inc. (KLDO) Healthcare & Pipeline Overview

Kaleido Biosciences, Inc. is a clinical-stage biotechnology firm pioneering microbiome metabolic therapies across diverse therapeutic areas like urea cycle disorders, ulcerative colitis, and hepatic encephalopathy. Leveraging strategic collaborations, the company focuses on advancing its pipeline of drug candidates, aiming to address significant unmet medical needs through innovative biological approaches.

What Is the Investment Thesis for KLDO?

Kaleido Biosciences, Inc. presents an investment thesis centered on its pioneering approach to microbiome metabolic therapies and a diverse clinical-stage pipeline targeting significant unmet medical needs. The company's strategic collaborations with institutions like Institute Gustave Roussy, Washington University, and Janssen provide external validation and potential pathways for advanced research and development, which could de-risk future clinical progress. Key value drivers include the advancement of specific drug candidates such as KB195 for urea cycle disorders, KB295 for ulcerative colitis, and KB174 for hepatic encephalopathy, each addressing conditions with substantial patient populations and limited effective treatments. The development of KB109 for COVID-19 also represents a potential catalyst, depending on its clinical progression and market relevance. As a clinical-stage entity, the company's financial profile reflects significant R&D investment, evidenced by a profit margin of -8178.3% and a gross margin of -113.6%. Future growth catalysts are intrinsically tied to positive clinical trial results, regulatory milestones, and the potential for new or expanded partnerships. However, the company operates with a market capitalization of 4K and a negative beta of -1.17, indicating a highly speculative profile typical of early-stage biotechnology firms, where successful clinical outcomes are critical for value creation.

Based on FMP financials and quantitative analysis

KLDO Key Highlights

• Market capitalization currently stands at $0.00B, reflecting its early-stage development and position within the biotechnology sector.
• Reported a profit margin of -8178.3%, indicative of substantial research and development expenditures typical for a clinical-stage company with no commercialized products.
• Exhibits a gross margin of -113.6%, consistent with a pre-revenue biotechnology firm investing heavily in its pipeline.
• The company's beta is recorded at -1.17, suggesting an inverse correlation with broader market movements, which is an unusual characteristic.
• Operates with a team of 76 employees, focusing resources on its specialized microbiome metabolic therapy research and development.

Who Are KLDO's Competitors?

KLDO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KLDO's Key Strengths?

• Specialized focus on microbiome metabolic therapies, a high-potential scientific area.
• Diverse clinical-stage pipeline targeting multiple significant unmet medical needs.
• Strategic collaborations with reputable academic and pharmaceutical partners.
• Headquartered in a major biotechnology hub (Lexington, Massachusetts).

What Are KLDO's Weaknesses?

• Clinical-stage company with no commercialized products and negative profit/gross margins.
• Small market capitalization ($0.00B) and reliance on external funding.
• High inherent risks associated with drug development, including clinical trial failures.
• Trades on the OTC market, potentially limiting liquidity and investor access.

What Could Drive KLDO Stock Higher?

• Positive clinical trial readouts for lead candidates like KB195, KB295, or KB174.
• Regulatory submissions or approvals for any of its pipeline drug candidates.
• Expansion or initiation of new strategic collaborations with pharmaceutical partners.
• Successful advancement of preclinical programs into clinical development in new therapeutic areas.
• Continued research and development efforts in multi-drug resistant infections and immuno-oncology.

What Are the Key Risks for KLDO?

• Financial-distress signal — its Altman Z-Score of -15.62 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for any of its drug candidates.
• Significant capital requirements and challenges in securing future funding for R&D given its clinical-stage status and OTC listing.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative therapies.
• Regulatory hurdles and potential delays in obtaining necessary approvals for its microbiome metabolic therapies.
• Lack of liquidity and transparency associated with trading on the "OTC Other" market, impacting investor confidence.

What Are the Growth Opportunities for KLDO?

• Growth opportunity 1: Advancement of KB195 for Urea Cycle Disorders. KB195 targets urea cycle disorders, a group of rare genetic conditions leading to ammonia buildup, which can cause severe neurological damage if untreated. Current treatments often involve strict dietary management and ammonia-scavenging medications, which have limitations. Successful progression of KB195 through clinical trials and potential regulatory approval could address a significant unmet medical need for these patients. The market for rare disease therapies often commands premium pricing, and a novel microbiome-based approach could offer a differentiated treatment option, potentially capturing a meaningful share within this specialized therapeutic area, contingent on demonstrating superior efficacy and safety profiles.
• Growth opportunity 2: Clinical Development of KB295 for Ulcerative Colitis. Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting millions globally, characterized by inflammation and ulcers in the colon. Despite existing therapies, a substantial portion of patients do not achieve sustained remission or experience significant side effects, highlighting a need for new, more effective, and better-tolerated treatments. KB295, as a microbiome metabolic therapy, represents a novel mechanism of action that could potentially modulate gut inflammation and restore microbial balance. Positive clinical trial results for KB295 could position Kaleido to tap into the large and growing inflammatory bowel disease market, offering a differentiated therapeutic option for patients struggling with this debilitating condition.
• Growth opportunity 3: Progress of KB174 for Hepatic Encephalopathy. Hepatic encephalopathy (HE) is a serious complication of liver disease, causing brain dysfunction due to the liver's inability to remove toxins from the blood. Current treatments focus on reducing ammonia levels, but recurrence rates remain high, and treatment options can have side effects. KB174's approach to modulating the microbiome to potentially mitigate ammonia production or its effects could offer a significant advancement. Successful clinical development and regulatory approval of KB174 would allow Kaleido to enter the market for liver disease complications, which represents a substantial patient population with ongoing needs for improved management strategies, thereby creating a new revenue stream for the company.
• Growth opportunity 4: Potential of KB109 for COVID-19 Disease. The development of KB109 for COVID-19 disease, while the pandemic's acute phase has evolved, still addresses the need for therapies that can mitigate disease severity or accelerate recovery, particularly for vulnerable populations or in the context of emerging variants. A microbiome-based intervention could potentially modulate the body's immune response or reduce viral load through novel mechanisms. If KB109 demonstrates clinical efficacy in ongoing or future studies, it could secure a position in the long-term management of COVID-19 or related respiratory viral infections, offering a differentiated approach compared to vaccines or antivirals, and potentially contributing to global health preparedness efforts.
• Growth opportunity 5: Expansion into Diverse Therapeutic Areas. Beyond its lead candidates, Kaleido Biosciences is actively pursuing programs in multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and other inflammatory bowel diseases. This broad pipeline strategy diversifies the company's risk and opens multiple avenues for future growth. Each of these areas represents a massive market with significant unmet medical needs, where microbiome modulation could offer transformative therapeutic benefits. Successful preclinical and early-stage clinical development in any of these areas could attract further partnerships, non-dilutive funding, or even lead to new lead candidates, significantly expanding Kaleido's long-term market potential and intellectual property portfolio.

What Opportunities Does KLDO Have?

• Successful progression of lead drug candidates through clinical trials and regulatory approval.
• Expansion of existing collaborations or formation of new strategic partnerships.
• Discovery and development of new microbiome-based therapies for additional indications.
• Increased scientific understanding and acceptance of microbiome's role in health and disease.

What Threats Does KLDO Face?

• Failure of clinical trials to demonstrate efficacy or safety for pipeline candidates.
• Intense competition from larger pharmaceutical companies and other biotech firms.
• Challenges in securing adequate funding for ongoing research and development.
• Adverse regulatory decisions or delays in the approval process.

What Are KLDO's Competitive Advantages?

• Proprietary scientific platform and expertise in microbiome metabolic therapies, a specialized and complex field.
• Developing a pipeline of novel drug candidates with unique mechanisms of action, potentially leading to strong intellectual property protection.
• Strategic collaborations with leading research institutions and a major pharmaceutical company (Janssen) providing access to resources and validation.
• Early-mover advantage in specific microbiome-targeted therapeutic areas, allowing for deeper understanding and development.

What Does KLDO Do?

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm established in 2015 and headquartered in Lexington, Massachusetts, dedicated to pioneering microbiome metabolic therapies. The company's core mission revolves around leveraging the power of the human microbiome to develop novel treatments for a wide spectrum of diseases. Its innovative approach focuses on understanding and modulating the gut microbiome to address underlying metabolic imbalances and disease pathways. The company's robust pipeline includes several specific drug candidates targeting significant medical conditions. Key among these is KB195, which is under development for the treatment of patients with urea cycle disorders, a group of genetic conditions that result in a build-up of ammonia in the body. Another prominent candidate is KB295, designed to treat ulcerative colitis, a chronic inflammatory bowel disease affecting the large intestine. Additionally, Kaleido is advancing KB174 for the treatment of hepatic encephalopathy, a decline in brain function that occurs as a result of severe liver disease. In response to global health challenges, the company also has KB109 in its pipeline, aimed at treating COVID-19 disease. Beyond these specific candidates, Kaleido Biosciences is actively advancing programs in other critical therapeutic areas. These include research and development efforts targeting multi-drug resistant infections, a growing global health threat, as well as chronic kidney disease, a progressive loss of kidney function. The company is also exploring applications in atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions, demonstrating a broad strategic focus on areas with high unmet medical needs. To bolster its research and development capabilities and accelerate its pipeline, Kaleido maintains strategic collaborations with leading institutions and pharmaceutical partners. These include partnerships with Institute Gustave Roussy, a renowned cancer research center, Washington University, a prominent academic research institution, and Janssen, a global pharmaceutical company. These collaborations are crucial for validating its scientific approach, accessing specialized expertise, and potentially facilitating future development and commercialization efforts. With 76 employees, Kaleido Biosciences operates as a focused entity within the biotechnology sector, striving to translate its scientific understanding of the microbiome into tangible therapeutic solutions.

What Products and Services Does KLDO Offer?

• Develops microbiome metabolic therapies for various diseases.
• Advances KB195 for urea cycle disorders.
• Progresses KB295 for ulcerative colitis.
• Researches KB174 for hepatic encephalopathy.
• Investigates KB109 for COVID-19 disease.
• Explores treatments for multi-drug resistant infections and chronic kidney disease.
• Engages in programs for atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.
• Collaborates with Institute Gustave Roussy, Washington University, and Janssen for research and development.

How Does KLDO Make Money?

• Focuses on research and development of novel drug candidates based on microbiome metabolic therapies.
• Aims to generate revenue through the successful commercialization of approved drug products in the future.
• Leverages strategic collaborations with academic institutions and pharmaceutical companies for shared development, expertise, and potential licensing agreements.
• Relies on external funding, grants, and equity financing to support its extensive clinical-stage pipeline and operational expenses.

What Industry Does KLDO Operate In?

Kaleido Biosciences, Inc. operates within the highly innovative and rapidly evolving Biotechnology industry, specifically focusing on the burgeoning field of microbiome metabolic therapies. This niche segment of healthcare is characterized by significant research and development investment, aiming to harness the therapeutic potential of the human microbiome to treat a wide array of diseases. The broader biotechnology market is driven by scientific advancements, an aging global population, and increasing prevalence of chronic diseases, creating a demand for novel treatment modalities. Kaleido's positioning as a clinical-stage company means it competes for scientific talent, funding, and intellectual property within a landscape populated by both larger pharmaceutical companies with microbiome divisions and numerous smaller, specialized biotech startups. The company's strategic collaborations are crucial in this competitive environment, providing access to expertise and resources. Success in this industry is heavily dependent on positive clinical trial outcomes and navigating complex regulatory pathways, with significant market potential for breakthrough therapies.

Who Are KLDO's Key Customers?

• Future patients suffering from urea cycle disorders, ulcerative colitis, hepatic encephalopathy, and other target conditions.
• Healthcare providers, including specialists and hospitals, who would prescribe and administer the company's approved therapies.
• Potential pharmaceutical partners seeking to license or co-develop microbiome-based therapies.
• Research institutions and government bodies interested in collaborative scientific advancements.

Company Profile

Kaleido Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Mark A. Wingertzahn. KLDO has traded publicly since 2019.

Kaleido Biosciences, Inc. (KLDO) Valuation Context

Valued at 4K, KLDO is classified as a micro-cap stock. Relative to its peer group, KLDO's quantitative score of 48/100 is below the peer average of 76/100.

F-Score 3/9Financial Health

Kaleido Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.62 places it in the distress zone, a signal of elevated financial risk.

KLDO Financials

KLDO Latest News

No recent news available for KLDO.

KLDO Analyst Consensus

KLDO MoonshotScore

KLDO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources